箕星是一家總部位于中國上海的生物制藥公司，致力于將創新科學和藥物帶給罹患嚴重危及生命健康疾病的中國患者。箕星由RTW Investments, LP于2019年投資創立，與全球多家生物技術公司開展合作，通過開發和商業化獨特創新的治療藥物，應對心血管和眼科疾病領域尚未滿足的醫療需求。憑借強勁且不斷壯大的產品管線、經驗豐富的管理團隊和以患者為中心的理念，箕星將為中國患者群體帶來持久而深遠的影響。更多信息，請訪問 www.jixing.com<\/a>。<\/p> \n

\n \n \n \n \n \n \n \n
<optgroup id="kgssg"></optgroup>
<center id="kgssg"></center>
久久久亚洲欧洲日产国码二区
*Lee J, Schotzinger J, et al. The Selective Aldosterone Synthase Inhibitor PB6440 Normalizes Blood Pressure In A Human Aldosterone Synthase-Transgenic Mouse Model Of Hypertension, Hypertension 2022<\/b>, 79<\/i>, <\/i>A121. <\/i><\/span><\/p> <\/td> \n <\/tr> \n
*Pitt B, Bhatt D, et al, Inhibition Of Aldosterone Synthesis In Non-human Primates By PB6440, The Novel Highly Selective And Potent CYP11B2 Inhibitor, Hypertension 2020<\/b>, 76, AP233.<\/i><\/span><\/p> <\/td> \n <\/tr> \n
*NCD Risk Factor Collaboration (NCD-RisC), Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants, The Lancet 2021<\/b>, 398, 10304, 957-980.<\/i><\/span><\/p> <\/td> \n <\/tr> \n
*國家心血管病中心<\/i>, <\/i>中國醫師協會<\/i>, <\/i>中國醫師協會高血壓專業委員會等<\/i>. <\/i>中國高血壓臨床實踐指南<\/i>[J]. <\/i>中華心血管病雜志<\/i>, 2022<\/b>, 50(11): 1050-1095. DOI: 10.3760\/cma.j.cn112148-20220809-00613.<\/i><\/span><\/p> <\/td> \n <\/tr> \n
*Wang Z, Chen Z, Zhang L, et al. Status of Hypertension in China: results from the China hypertension survey, 2012– 2015. Circulation 2018<\/b>; 137: 2344–2356.<\/i><\/span><\/p> <\/td> \n <\/tr> \n <\/tbody> \n <\/table> \n<\/div> \n
<\/p>"]; $("#dvExtra").html(content_array[0]);})();

<center id="kgssg"></center>